Chengbin Wu
Company: Epimab Biotherapeutics
Job title: Chief Executive Officer
Seminars:
A Tetravalent Bispecific T-Cell Engager with Optimized Efficacy & Safety Profile for Oncology & Autoimmune Indications 2:45 pm
Developing a tetravalent TCE platform FIT-Ig with reduced CRS Clinical validation of FIT-Ig based TCE for hematology and autoimmunity Optimizing a FIT-Ig based TCE for solid tumorsRead more
day: Day 1